Meibomian Gland Dysfunction (MGD) and Tear Cytokines After Cataract Surgery According to Preoperative Meibomian Gland Status

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02411487

Enrollment

Registered

2015-04-08

Start date

2015-03-16

Completion date

2015-08-03

Last updated

2017-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

To investigate the possible mechanisms by which cataract surgery aggravates meibomian gland dysfunction (MGD), the investigators evaluated the changes in tear cytokines and ocular surface parameters after cataract surgery according to the preoperative MGD grade.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

55 Years to 80 Years

Healthy volunteers

Inclusion criteria

* males or non-pregnant females aged between 55 to 80 years-old.

Exclusion criteria

* had a history of ocular diseases, such as ocular infection, ocular allergy, and autoimmune disease, as well as patients with continuous use of topical ocular medications before surgery, or histories of ocular surgery or ocular injury.

Design outcomes

Primary

Measure	Time frame	Description
inflammatory tear cytokine concentration	1 month after cataract surgery	comparison of tear cytokines (IL-2,4,10,17a, INF-r, TNF-a) concentrations in patients with or without newly diagnosed chronic GVHD after SCT using a multiplex immunobead assay
ocular surface staining	1 month after cataract surgery	—
tear film break-up time,	1 month after cataract surgery	—
conjunctival injection,	1 month after cataract surgery	—
Schirmer's test I	1 month after cataract surgery	—
ocular surface disease index	1 month after cataract surgery	—

Countries

South Korea

Outcome results